Non-profits appeal to FDA on Avastin

Susan G. Komen for the Cure and the Ovarian Cancer National Alliance sent a letter to FDA urging the agency to allow continued use of Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY) for breast cancer despite an FDA panel's recommendation to remove the indication from the drug's label. The letter said that some patients receiving Avastin enjoy better than modest results and expressed concern that if breast cancer is removed from the label, third party payers would refuse to cover off-label use for breast cancer. ...